Bristol-Myers Squibb Company (BMY)
NYSE: BMY · IEX Real-Time Price · USD
44.03
-0.08 (-0.18%)
At close: May 17, 2024, 4:00 PM
44.15
+0.12 (0.27%)
Pre-market: May 20, 2024, 8:21 AM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $45.53B in the twelve months ending March 31, 2024, down -0.68% year-over-year. Revenue in the quarter ending March 31, 2024 was $11.87B with 4.66% year-over-year growth. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B, a decrease of -2.50%.
Revenue (ttm)
$45.53B
Revenue Growth
-0.68%
P/S Ratio
1.96
Revenue / Employee
$1,335,308
Employees
34,100
Market Cap
89.25B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
| Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
| Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
| Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
| Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
| Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
| Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
| Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
| Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
| Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
| Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
| Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
| Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
| Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
| Dec 31, 2005 | 18.61B | -775.00M | -4.00% |
| Dec 31, 2004 | 19.38B | 727.00M | 3.90% |
| Dec 31, 2003 | 18.65B | 2.45B | 15.09% |
| Dec 31, 2002 | 16.21B | -1.84B | -10.18% |
| Dec 31, 2001 | 18.04B | 506.00M | 2.89% |
| Dec 31, 2000 | 17.54B | 1.04B | 6.28% |
| Dec 31, 1999 | 16.50B | 1.44B | 9.57% |
| Dec 31, 1998 | 15.06B | -1.64B | -9.82% |
| Dec 31, 1997 | 16.70B | 1.64B | 10.86% |
| Dec 31, 1996 | 15.07B | 1.30B | 9.43% |
| Dec 31, 1995 | 13.77B | 1.78B | 14.88% |
| Dec 31, 1994 | 11.98B | 571.00M | 5.00% |
| Dec 31, 1993 | 11.41B | 257.00M | 2.30% |
| Dec 31, 1992 | 11.16B | 585.00M | 5.53% |
| Dec 31, 1991 | 10.57B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CVS Health | 360.94B |
| McKesson | 308.95B |
| Cigna | 206.00B |
| HCA Healthcare | 66.72B |
| Sanofi | 51.60B |
| GSK | 39.41B |
| Gilead Sciences | 27.45B |
| Boston Scientific | 14.71B |
BMY News
- 3 days ago - New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis - Business Wire
- 4 days ago - Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma - Business Wire
- 4 days ago - US FDA approves expanded use of Bristol's cancer cell therapy - Reuters
- 9 days ago - Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial - Business Wire
- 13 days ago - Bristol Myers Squibb to Participate in Upcoming Investor Conferences - Business Wire
- 14 days ago - European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite - Business Wire
- 14 days ago - U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) - Business Wire
- 19 days ago - Should You Pick Bristol Myers Squibb Stock At $45? - Forbes